Calcium/calmodulin-dependent protein kinase II (CaMKII ) is an important regulator of cardiac contractile function and dysfunction and may be an unwanted secondary target for anti-cancer drugs such as sunitinib and imatinib that have been reported to alter cardiac performance. This study aimed to determine whether anti-cancer kinase inhibitors may affect CaMKII activity and expression when administered in vivo.
Introduction
Cardiotoxicity is a common side effect of many 'successful' anti-cancer agents (Curigliano et al., 2010) . Although improvements in regression of cancer growth and metastasis have been observed with these agents, a range of cardiac toxicities can occur. These include ECG changes and left ventricular (LV) contractile dysfunction, leading in some cases to congestive heart failure.
One class of anti-cancer agents with proven cardiotoxic effects are the kinase inhibitors (Cheng and Force, 2010) Kinases, in particular tyrosine kinases, play an important role in tumour angiogenesis and cell proliferation. Inhibition of these enzymes slows tumour progression leading to shrinkage of the tumour mass. Unfortunately, and in spite of their potential for targeted effects, some members of this family of inhibitors exhibit marked cardiotoxicity. Imatinib was the first of these kinase inhibitors to gain FDA approval and cardiotoxicity was not predicted by preclinical studies.
Following approval, however, it was reported that development of heart failure was associated with imatinib treatment in some patients (Kerkela et al., 2006) .
Unlike imatinib, sunitinib is a kinase inhibitor that is clearly associated with clinical cardiotoxicity.
Preclinical evaluations have shown sunitinib to cause LV hypertrophy and hypertension (Maayah et al., 2014; Blasi et al., 2012) . Clinically, prolongation of the QT interval has been observed (Bello et al., 2009 ) and a retrospective study found that 15% of sunitinib-treated patients developed symptomatic grade 3/4 LV dysfunction (Telli et al., 2008) whilst in another study 8% of patients developed heart failure following 33.6 weeks median treatment duration (Chu et al., 2007) .
Sunitinib has multiple targets including vascular endothelial growth factor receptors, platelet derived growth factor receptors, FMS-like tyrosine kinase 3 and c-kit. A key issue with the limited selectivity of sunitinib is the likelihood of 'off-target toxicity' caused by the action of sunitinib on proteins other than those that are recognised targets (Cheng and Force, 2010) . One example recently identified was AMP activated protein kinase. This kinase has an essential role in metabolic homeostasis in the heart and, as such, alterations in its activity following sunitinib treatment have been shown to cause compromised cardiac myocyte function (Kerkela et al., 2009 ). There could potentially be a large number of 'off-target' effects of sunitinib (and indeed other members of the kinase inhibitor family) (Ghoreschi et al., 2009 ). However, these additional targets and the contribution they make to the cardiotoxic properties of these small molecule inhibitors have yet to be fully assessed.
One kinase that plays a crucial role in cardiac function is calcium/calmodulin dependent protein kinase II (CaMKII). CaMKII exists as four different isoforms, , , and , with the isoform being the predominant isoform expressed in the heart. As well as acting as a key modulator of cardiac calcium handling and contractility, CaMKII has also been suggested to regulate the cardiac inflammatory response, transcriptional events and non-contractile cardiac cell proliferation (Currie et al., 2011; Martin et al., 2014) . Importantly, CaMKII is recognised not only as a critical modulator of normal cardiac function, but is also established as a fundamental molecular switch that, when excessively expressed and activated, can trigger pathophysiological events leading ultimately to heart failure (Anderson et al., 2007) . Pathophysiological consequences of increased CaMKII activity include a range of effects on cardiac ion channels influencing depolarisation, cardiac excitability and repolarisation of cardiac myocytes (Anderson, 2007) . Dysfunctional sarcoplasmic reticulum (SR) Ca 2+ handling is evident following CaMKII -mediated hyperphosphorylation of the SR Ca 2+ release channel, the ryanodine receptor (RyR), which leads to increased diastolic Ca 2+ release and a propensity for cardiac arrhythmias (Wehrens et al., 2004) . As well as coordinating contractile dysfunction, CaMKII activation can also increase the activity of pro-inflammatory mediators and the development of fibrosis. As such, it links a number of both acute and chronic pathological events in the progression of heart disease and has been referred to as a prime candidate for therapeutic targeting (Currie et al., 2011; Anderson, 2007) .
The possibility that cardiotoxic effects of kinase inhibitors may be mediated via CaMKII has not previously been investigated in vivo. This is surprising given the overwhelming recognition that elevated CaMKII is central to cardiac pathophysiology. Previously, we have optimised conditions for studying the acute effects of drugs on indices of cardiac contractility and haemodynamics in an anaesthetised guinea pig model . In this study we have also developed the guinea pig model to allow assessment of more prolonged dosing of drugs on cardiovascular function. Using these techniques, we have compared the effects of sunitinib and imatinib with recognised positive and negative inotropes. Applying an integrated approach we have also assessed in parallel, the effects of these drugs on CaMKII expression and CaMKII activity in LV tissue taken from the same animals.
Methods

Animals and anaesthesia
All animal experiments were performed in accordance with the UK Animals (Scientific Procedures) and fluanisone 10 mg ml −1 ); 1 part Hypnovel (midazolam HCl 5 mg ml −1 ) and 2 parts water made up freshly each day) for echocardiography assessments, and maintained for haemodynamic assessment with sodium pentobarbital as described above. A different anaesthetic regimen was used for the chronic experiments taking into account the requirement for recovery following initial echocardiography assessment. Although Hypnorm® and Hypnovel® can cause a decline in heart rate , this is not observed until after 15 minutes and at higher concentrations than that used here. Full details of animal housing conditions, diet, surgical preparation and all equipment have been published previously . days. All drugs were dissolved in 0.1% ascorbic acid in 0.9% w/v NaCl except imatinib which was dissolved in 0.9% w/v NaCl. On day 6, guinea pigs were re-anaesthetised and echocardiography was repeated. Haemodynamic assessment was then performed as described above. At the end of this animals were euthanised by removal of the heart.
Tissue preparation
The heart was weighed following removal and a transverse section taken through the right and left ventricle and fixed in 10% formalin for subsequently histological analysis. The remaining LV was cut into chunks, snap frozen in liquid nitrogen and stored at -80°C. As required, LV tissue was homogenised in buffer containing 20 mM Tris-HCl, pH7.2, 1 mM DTT, phosphatase inhibitors (0.5 mM calyculin A, 4 mM Na orthovanadate) and protease inhibitors (cocktail set V, EDTA free; Calbiochem). The total protein content was determined using the Coomassie Plus protein assay (Pierce).
Immunoblotting LV homogenates were subjected to SDS-PAGE using the NuPAGE system (Invitrogen); 10% BisTris gels for CaMKII and 3-8% Tris-Acetate gels for RyR. Antibodies were as follows: Custom made polyclonal antibody (rabbit IgG) against the C terminus of CaMKII (1:5000, Eurogentec), rabbit polyclonal anti-phosphoRyR (Ser-2815) IgG (1:2000, Badrilla), mouse monoclonal anti-GAPDH IgG (1:80,000, Abcam). Either goat anti-mouse or anti-rabbit-horseradish peroxidise conjugate (Sigma and GE Healthcare) were used as secondaries. Films were quantified using a GS800 calibrated densitometer and Quantity One software (Bio-Rad Laboratories Ltd.). GAPDH was used for intra-gel normalisation. CaMKII:GAPDH and pSer2815-RyR:GAPDH ratios were calculated for each sample and these were then normalised to an untreated sample (aliquots from the same preparation) included in every gel to allow inter-gel normalisation. The latter normalisation was performed due to the number of samples, which had to be run across several different gels.
CaMKII activity assay
CaMKII activity was determined in triplicate in LV tissue homogenates by measuring the incorporation of -32 P into a CaMKII peptide substrate, autocamtide-2 as described previously (Anthony et al., 2007) . Controls included homogenates measured in the absence of Ca 2+ (5mM EGTA), absence of substrate, and inclusion of autocamtide inhibitory peptide (AIP), a recognised CaMKII inhibitor. Individual activity values were converted to pmol of phosphate incorporated min -1 g protein -1 and normalised to the calculated activity of an untreated sample included in every assay, in line with immunoblotting analyses.
Plasma drug and cardiac troponin I concentrations
In acute and chronic experiments, blood samples were collected in 1.3 ml lithium heparin tubes from the open chest at the end of the haemodynamic assessment and immediately after removal of the heart. Plasma was prepared by centrifugation (AccuSpin MicroR centrifuge, Fisher Scientific) at 3000 rpm for 10 min, aliquoted and stored at -80°C until analysis. Total plasma drug concentrations were determined by HPLC-MS/MS. On day 6 of the chronic dosing study blood samples were also collected for determination of plasma cardiac troponin I using the ADVIA Centaur® CP Immunosystem cTnI-Ultra TM assay (Medical Siemens).
Drugs
Fentanyl, Hypnorm® and Hypnovel® were obtained from veterinary wholesalers through the Biological Procedures Unit at the University of Strathclyde. Sodium pentobarbital, isoprenaline
HCl and verapamil were obtained from Sigma-Aldrich. Sunitinib and imatinib were purchased from Sequoia Research Products Ltd. All drugs were dissolved in 0.9% w/v NaCl for acute administration or 0.1% acidified saline for chronic administration.
Data Analysis
Results are presented as mean ± SEM. In acute experiments, haemodynamic data were averaged over 5 s at 1, 2, 3, 4, 5, 10 and 15 min after the start of each infusion and drug effects were determined by Kruskal-Wallis tests. At the end of the chronic dosing experiments, haemodynamics were averaged over 15 min and drug effects were assessed by comparison to the vehicle group using a one way ANOVA followed by Dunnett's test. Haemodynamic effects are presented as a % change from baseline to allow clear comparison across drug groups. For echocardiography experiments, pre (day 0) and post (day 6) treatment measurements were compared using Student's paired t-test. Kruskal-Wallis tests were used for comparisons of CaMKII expression, CaMKII activity, pSer2815-RyR expression and cardiac troponin I concentrations among groups because some of the data were not distributed normally.
Results
Acute sunitinib treatment caused a decrease in LVdP/dt max that was accompanied by a fall in heart rate and blood pressure Sunitinib decreased LVdP/dt max in a dose-dependent manner with significant changes appearing at the beginning of infusion of the second dose ( Figure 1 ). As expected, the negative inotrope verapamil also reduced LVdP/dt max whereas the positive inotrope isoprenaline caused rapid dosedependent increases (Figure 1 ). The changes in heart rate induced by these drugs were similar to their effects on LVdP/dt max ; sunitinib and verapamil decreased heart rate and isoprenaline caused an increase ( Figure 2A ). However, although sunitinib and verapamil caused significant, dosedependent reductions in systolic and diastolic arterial BP, isoprenaline did not alter either parameter significantly ( Figure 2B and C). Acute treatment with vehicle had no significant effects on any of the parameters.
CaMKII activity was significantly reduced following acute sunitinib treatment
Quantitative immunoblotting for CaMKII revealed no differences in expression of the protein in LV homogenates across all acute treatment groups ( Figure 3A ). The same homogenates were then assessed for CaMKII activity. When compared with vehicle, sunitinib and verapamil treatment significantly decreased CAMKII activity and, as expected, acute isoprenaline administration increased CAMKII activity. ( Figure 3B ).
To test the sensitivity of the CaMKII activity assay, LV homogenate was assessed alone, in the presence of the CaMKII inhibitor AIP (3 µM and 10 µM), in the absence of CaMKII peptide substrate and in the presence of 5 mM EGTA to remove extracellular Ca 2+ . All of these treatments resulted in inhibition of CaMKII basal activity as expected, confirming the sensitivity of the assay ( Figure 3C ).
Chronic administration of either sunitinib or imatinib had no significant effects on LVdP/dt max , heart rate, blood pressure or fractional shortening
Echocardiography was used to assess left ventricular diameter and fractional shortening (FS) before and after chronic drug administration. A short-axis view of the guinea pig heart is shown in Fig. 4A along with a corresponding M-mode recording. LV diameters and FS remained unchanged following chronic administration with sunitinib and imatinib. LVDD was increased by 23% and LVSD by 89% in the isoprenaline group. LVSD was increased by 34% following verapamil administration. FS was decreased significantly in both the isoprenaline and verapamil groups by 28% and 24%, respectively ( Figure 4B ).
Sunitinib and imatinib also had no effect on LVdP/dt max during the final haemodynamic assessment whereas this index of cardiac contractility was decreased significantly in the verapamil group (Table 1) . None of the drugs caused significant changes in heart rate and the only drug which affected BP was verapamil which reduced both systolic and diastolic arterial BP significantly (Table 1) .
There were no changes in heart:body weight ratio (Table 1 ) and no cardiac histopathological changes following any of the chronic drug treatments.
CaMKII expression and CaMKII activity were both significantly increased by chronic sunitinib and imatinib administration Expression of CaMKII protein increased in response to chronic treatment in all drug groups compared to the vehicle group ( Figure 5 ). Verapamil caused the greatest increase in expression (96%), followed by imatinib (62%), sunitinib (23%) and isoprenaline (22%). Parallel experiments were performed to measure changes in CaMKII activity following chronic drug treatment. The greatest increase was in the sunitinib group (110%), followed by isoprenaline (78%), verapamil (70%) and imatinib (50%) ( Figure 6A ).
CaMKII-dependent phosphorylation of RyR was increased following chronic administration of sunitinib and imatinib
In order to confirm the increase in activity measured using the CaMKII activity assay, quantitative immunoblotting of the CaMKII-selective phosphorylation site on RyR, serine 2815 (pSer2815-RyR), was used as a second assessment of CaMKII activity. All chronic treatments resulted in an increase in pSer2815-RyR expression when compared with vehicle treatment ( Figure 6B ). Again the largest increase was with sunitinib treatment (123%), but this time it was followed by imatinib (61%) then isoprenaline and verapamil which were similarly effective causing increases in pSer2815-RyR expression of 16 and 12%, respectively.
Plasma drug and cardiac troponin I concentrations
In the acute phase studies, total plasma drug concentrations achieved at the end of the dosing period were: sunitinib 25.4 ± 8.3 µM and verapamil 7.8 ± 2.9 µM. In the chronic dosing groups, total plasma drug concentrations, respectively, were: sunitinib 0.01 ± 0.002 µM (clinically relevant concentration is 0.06mM) ; imatinib 1.36 ± 0.38 µM (clinically relevant concentration is 2mM); verapamil 0.16 ± 0.02 µM. Plasma drug concentrations for isoprenaline could not be determined as a suitable method could not be established.
Plasma cardiac troponin I concentrations for each chronic treatment group were: sunitinib 3.56 ± 1.13 ng ml -1 ; imatinib 2.24 ± 0.54 ng ml -1 verapamil 9.16 ± 4.76* ng ml -1 ;isoprenaline 1.80 ± 0.37 ng ml -1 ; vehicle 1.42 ± 0.47 ng ml -1 (* indicates P<0.05 compared to vehicle group, Kruskal-Wallis test).
Discussion
The central finding of this study is that chronic treatment with anti-cancer kinase inhibitors, sunitinib and imatinib, increased cardiac CaMKII expression and CaMKII activity in guinea pigs in the absence of any overt cardiac dysfunction. Since both agents have been associated with cardiotoxicity in the clinic these changes could reflect early adaptations by the heart to these anticancer kinase inhibitors which could precede the onset of contractile dysfunction. We have specifically examined the anti-cancer agents sunitinib and imatinib; however, the potential role of CaMKII in modulating cardiotoxic effects of other anti-cancer therapies should not be overlooked.
Acute drug effects
Acute treatment with sunitinib (3 x 15 min infusions) caused significant haemodynamic effects in anaesthetised guinea pigs. With cumulative infusions there was a significant decrease in LVdP/dt max as well as significant decreases in both systolic and diastolic BP. Decreases in blood pressure of such a magnitude would be expected to result in a reflex tachycardia based on the known baroreflex sensitivity of this model ; however, sunitinib caused a dosedependent decrease in heart rate. In the acute studies a large dose range was explored, from an initial dose, expected to yield clinically relevant plasma concentrations, to higher doses that yielded concentrations well in excess of efficacious concentrations. Since sunitinib is a relatively nonselective kinase inhibitor, the cardiovascular effects, observed at supratherapeutic exposures, are likely due to actions at other secondary molecular targets (eg tyrosine kinases or GPCRs) (Sutent FDA Pharm Review) . Previous experiments with sunitinib in rats have shown that it causes a dosedependent hypertension, possibly due to its inhibition of VEGF signalling; however, this effect is only apparent after repeated dosing (Isobe et al., 2014 , Blasi et al., 2012 .
Overall, these results suggest that acute administration of sunitinib, at high doses, causes a negative chronotropy, and may also reduce inotropy. A similar haemodynamic profile was observed with the calcium channel antagonist verapamil in agreement with previous studies in this model . In contrast, isoprenaline increased LVdP/dt max and heart rate, in line with its positive inotropic and chronotropic actions, and had no effect on systolic or diastolic arterial BP.
It is well known that LVdP/dt max can be influenced by changes in cardiac loading and heart rate (Wallace et al., 1963; Markert et al., 2012) . Previous studies in guinea pigs have shown LVdP/dt max to be positively influenced when mean arterial BP is >80 ± 8 mmHg and negatively influenced when mean arterial BP is <39 ± 3 mmHg . In addition, LVdP/dt max increased with increases in heart rate to peak values of 220-249 beats min -1 , after which LVdP/dt max decreased with further increases in heart rate . In the present study, during the final infusions of both sunitinib and verapamil , mean arterial BP and heart rate decreased below 39 mmHg and 220bpm, respectively. In isoprenaline experiments mean arterial BP was not significantly altered and heart rate was maintained above 249 beats min -1 . Therefore, it must be borne in mind that the changes in LVdP/dt max induced with sunitinib and verapamil administration may also be a consequence of the concurrent changes in heart rate and/or arterial BP.
Interestingly, when CaMKII was assessed from acute drug-treated hearts, although there was no change in CaMKII protein expression with any of the drug treatments (which is unsurprising over such a short time scale), changes in activity were observed. Specifically, sunitinib caused a significant decrease in CaMKII activity as did verapamil. Acute administration of isoprenaline caused CaMKII activity to increase. This is in agreement with previous studies in rats and mice (Yoo et al., 2009; Grimm & Brown 2010) but is the first time this relationship has been demonstrated in guinea pigs in vivo. Previous work has suggested that a significant element of -adrenergic signalling is mediated via CaMKII and that this contributes to the pathophysiology observed in heart failure (Grimm & Brown 2010). It may also be the case that drugs already used in the treatment of various cardiomyopathies (such as -blockers) can target CaMKII albeit nonspecifically (Currie et al., 2011; Grimm & Brown 2010) . Given the pivotal role that CaMKII plays in cardiac function and dysfunction and the potential it has as a target for mediating therapeutic effects, it seems likely that it could also be an unwanted secondary target for drugs exhibiting adverse cardiac side effects. This is of interest when examining acute sunitinib treatment where there is evidence for significantly altered CaMKII activity.
Chronic drug effects
Chronic drug administration via mini-pump delivery over 6 days used the same standard inotropes and included imatinib as well as sunitinib. Ideally, it would have been beneficial to include chronic administration of a CaMKII selective modulator. We had originally planned to include AIP; however, the costs involved in administering this peptide over 6 days in the guinea pig were prohibitive. Chronic selective inhibition of CaMKII has proved feasible in mice where studies have administered the CaMKII inhibitor KN-93 or used genetic models where the autoinhibitory domain of the kinase is targeted (Zhang et al., 2005; Kaurstad et al., 2012) . These studies provide support to the capability of chronic and selective targeting of CaMKII.
In the present study, chronic administration of sunitinib and imatinib had no obvious adverse effects on cardiac function and haemodynamics. Larger group sizes may have increased the chance of finding rare cardiotoxic effects, but the guinea pigs used here were healthy with no co-morbidities which may predispose to such effects. Another likely explanation for the absence of effects on cardiac function is related to the duration of treatment which is far short of the weeks/months of treatment given to patients. Other in vivo animal studies investigating cardiotoxicity have been performed over longer durations with periods of up to 6 weeks for imatinib (Kerkela et al., 2006 , Wolf et al., 2010 and up to 5 weeks for sunitinib (Kerkela et al., 2009) ; however, it is of interest that in the later study, sunitinib had no effects on cardiac function in the mouse and caused only an apparent loss of cardiomyocytes. In the current study the effects of imatinib, and sunitinib in particular, on CaMKII expression and activity were highly significant over 6 days of treatment.
Despite CaMKII being highlighted in reports reviewing drug-induced cardiotoxicity (Zhou et al., 2010; Stumman et al., 2009) , no previous studies have investigated the effects of imatinib or sunitinib on cardiac contractility and CaMKII expression and/or activity. However, interestingly a recent study examining the effects of imatinib on rat neonatal cardiomyocytes has reported significant activation of CaMKII activity in response to the anti-cancer drug (Barr et al., 2014) .
Clinically relevant doses of 2mM and 5mM imatinib were used and, in response to both concentrations, there was significant elevation of Thr17 phosphorylation of phospholamban and Ser 2814 phosphorylation of the ryanodine receptor -both selective substrates for CaMKII. This resulted in enhanced sarcoplasmic reticulum function as well as activation of NFAT (nuclear factor of activated T cells) signalling. This imatinib-dependent activation of Ca 2+ -handling resulted in pathological hypertrophy and necrotic cell death. These results are particularly pertinent to the current study where along with measurement of CaMKII activity via selective incorporation of phosphate into a specific peptide substrate we also show evidence for increased pSer2815-RyR following chronic imatinib and sunitinib treatment.
In the current study echocardiography assessment showed significant decreases in FS following chronic isoprenaline treatment; however, there was no increase in heart:body weight ratio and no histopathological effects suggesting that chronic -adrenoceptor activation had not yet induced heart failure. The decrease in FS was associated with left ventricular (LV) dilatation indicated by the significant increase in both LV end-diastolic and end-systolic diameter and also the increase in LVEDP. Decreased contractile performance and increased CaMKII expression and activity are indicative of compromised cardiac function which can ultimately lead to heart failure (Anderson et al., 2007) . Isoprenaline has been administered chronically in several studies in mice (Kudej et al., 1997; Friddle et al., 2000) and rat (Kitagawa et al, 1997 , Takeshita et al., 2008 , but less commonly in guinea pig (Maisel et al., 1987) . In all of these studies, chronic isoprenaline administration caused cardiac hypertrophy. CaMKII expression and activity are known to be increased following chronic -adrenoceptor stimulation and in hypertrophy and heart failure (Zhang et al., 2003) . Taken together this evidence supports the effects of chronic isoprenaline treatment observed in the current study.
A decrease in fractional shortening and LVdP/dt max was observed following administration of verapamil. It was anticipated that chronic verapamil treatment would decrease contractile performance, given the negative inotropic effects of this drug. This has been shown previously in rabbits chronically treated with verapamil (2 mg kg -1 day -1 , 28 days) where a significantly lower force of contraction and a depressed contractile response to epinephrine in papillary muscles isolated from verapamil-treated animals was observed (Bosnjak et al., 1991) . By blocking Ca 2+ entry into cardiomyocytes, theoretically, verapamil should result in a decrease in CaMKII activity and this was apparent following acute verapamil treatment. However, chronic verapamil administration caused CaMKII expression and CaMKII activity to increase. Although this was initially unexpected, similar effects of chronic verapamil treatment have been reported elsewhere in the rat (Zhou, 2010) . Chronic verapamil treatment (15 mg kg -1 day -1 ) caused several biochemical and functional changes to Ca 2+ handling proteins, resulting in altered cardiac function. Of particular relevance to the findings here, were the observations of increased CaMKII expression and hyperphosphorylation of RyR. Interestingly, these changes occurred in the absence of cardiac hypertrophy or fibrosis following chronic verapamil treatment (Zhou, 2010) . Although, plasma cardiac troponin I was significantly increased in the current study, perhaps indicating cardiac damage, histological analysis revealed no morphological abnormalities. Thus, biochemical changes may result in adverse effects on cardiac function without evidence of structural deficits.
Potential mechanisms involved in effects on CaMKII
It seems unlikely that imatinib and sunitinib are directly targeting CaMKII as these drugs were designed as kinase inhibitors rather than kinase activators. It is possible that these drugs affect other signalling molecules up-or downstream of CaMKII which subsequently increase CaMKII expression and CaMKII activity. A potential link lies in the fact that CaMKII can be activated in vitro and in vivo by reactive oxygen species (ROS) acting via oxidation of Met281/282 in the autoregulatory domain (Erickson et al., 2008) . Mitochondria are an important source of ROS within most mammalian cells, and this underlies oxidative damage in many disease states (Murphy, β009) . Mitochondrial perturbation and toxicity have been identified as a "common theme" in druginduced cardiotoxicity (Force et al., 2011) and imatinib and sunitinib have been linked to mitochondrial injury and abnormalities in mice, rat and humans (Kerkela et al., 2006; Wolf et al., 2010) . In addition, sunitinib increased the generation of ROS in vitro (Mellor et al., 2011; Zhuang et al., 2011) . More recently, CaMKII activity has been identified as having a central role in the mitochondrial Ca 2+ entry that precedes myocardial dysfunction and cell death (Joiner et al., 2012) .
Taken together these findings suggest CaMKII can be activated by oxidation resulting from ROS, in conjunction with cross-talk and potential feedback to the mitochondria.
It is interesting to note that in vitro studies in rat neonatal cardiac myocytes suggest CaMKII inhibition can at least partly reverse the cardiotoxic effects of imatinib (Barr et al., 2014) . Myocytes treated with AIP or infected with a virus containing a dn-CaMKII showed less imatinib-induced hypertrophic remodelling. In addition, imatinib-induced nuclear translocation of NFAT was blocked by the calcineurin inhibitor FK506, the CaMKII inhibitor AIP and by the L-type Ca 2+ channel blocker Nifedipine. The authors suggest that imatinib increases the pool of cellular Ca 2+ available for activation of CaMKII and calcineurin-NFAT nuclear translocation which ultimately results in pathological hypertrophy.
In the present study, we aimed to achieve clinically relevant concentrations of the test drugs in the chronic dosing protocol. In general, this was achieved, with a mean total plasma concentration of 1.36 mM and 0.01 mM achieved in the chronic phase for imatinib and sunitinib, respectively, compared to clinically efficacious concentrations of 2 mM (980 ng/mL) and 0.06 mM (25 ng/mL), respectively (Kitagawa et al., 2013) . It is worth noting that the concentration of imatinib achieved in our chronic dosing is in line with the concentration (2mM) used in vitro (Barr et al., 2014) where significant CaMKII activation was observed. The concentration of verapamil achieved was also in the clinical range (0.16 mM vs 0.23 mM (105 ng.mL) (Freedman et al., 1981) .
In conclusion, findings presented here show for the first time that sunitinib and imatinib treatments affect CaMKII in the heart with chronic treatments leading to significantly increased CaMKII expression and activity. Given the strong link between chronic CaMKII elevation and cardiovascular dysfunction, this may be a mechanism by which sunitinib and imatinib exert at least part of their cardiotoxic side-effects. Further investigation is required to verify the mechanism of action of these kinase inhibitors upon CaMKII. (beats min -1 ), isoprenaline 266 ± 6, verapamil 284 ± 9, sunitinib 238 ± 7, vehicle 267 ± 16; Systolic blood pressure (mmHg), isoprenaline 62 ± 7, verapamil 59 ± 1, sunitinib 56 ± 2, vehicle 57 ± 3.
Diastolic blood pressure (mmHg), isoprenaline 39 ± 5, verapamil 33 ± 2, sunitinib 39 ± 2, vehicle 33 ± 2. Mean ± SEM; n=4. *p<0.05 compared to value within group at time 0 min, Kruskal-Wallis test. 
